Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Income Before Tax

Profit after all operating and non-operating items but before income tax.

Immunome, Inc.NASDAQ: IMNM

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -$85.78M, compared with -$57.46M a year earlier. Trailing-twelve-month income before tax was -$282.65M.

Context

  • Income before tax amounted to 3060.0% of revenue in FY2025, down 180.4 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$85.78M or moves back toward the trailing-twelve-month quarterly average of -$70.66M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$85.78M-17.3% QoQ
Last fiscal yearDec 2025
-$212.39M+27.5% YoY
LTMSep 2026
-$282.65M-26.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.3%——
1 year+27.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(212.39M) USD
Year-over-year change
+27.5%

Income Before Tax vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.9% is the 6th highest of 11, against a peer median of -21.7%.
IMNM Competitors
Income Before Tax for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026-$7.82M USD+65.7%—2.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026-$34.95M USD-67.5%——
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026-$35.76M USD-37.8%——
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M USD-6.7%——
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M USD-29.5%—45.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M USD-14.0%——
STROSutro Biopharma, Inc.LTM Mar 2026-$153.72M USD+36.7%—154.3%
IMTXImmatics N.V.LTM Mar 2026-€215.35M EUR-1111.0%—577.4%
BCYCBicycle Therapeutics plcLTM Mar 2026-$217.62M USD-4.3%—342.7%
IMNMImmunome, Inc.LTM Sep 2026-$282.65M USD-26.9%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M USD-37.7%—275986.6%
Peer median (excluding IMNM) —-21.7%—248.5%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.